Articles tagged with 'unpublished' | Bayer

Through its new "Better Farms, Better Lives" initiative, Bayer will complement its current commitment to support smallholder farmers in key countries by donating seeds and crop protection inputs / The donations help boost food security by supporting ...

Stockholders able to exercise right to submit questions and cast votes in a timely manner / Online stockholders’ meeting enables proposed dividend of 2.80 euros per share for 2019 to be paid on time and in full / Baumann: "Reliability for our stockho...

Group plans to exit Animal Health business, the Consumer Health brands Coppertone™ and Dr. Scholl’s™, and sell its 60-percent interest in Currenta, a site services provider in Germany / Efficiency and structural measures set to enhance competitivenes...

The safety and efficacy profile of Jivi has been demonstrated in more than five years of clinical studies / Prophylaxis with Jivi enables sustained factor VIII concentrations in the blood over time

First treatment with a tumor-agnostic indication at the time of initial FDA approval / Larotrectinib approved under the brand name Vitrakvi® / 75% overall response rate (ORR) (95% CI, 61%, 85%) [22% complete response (CR) and 53% partial response (PR...

Group sales increase by 1.9 percent (Fx & portfolio adj.) to 9.905 billion euros / EBITDA before special items level year on year at 2.202 billion euros / Business performance at Pharmaceuticals remains strong / Consumer Health with increase in sales...

The safety and tolerability observed in the trial were consistent with previously published data on darolutamide

Data presented across 122 adult and pediatric patients (55 patients from primary dataset plus supplementary dataset with 67 additional patients) with TRK fusion cancer across various tumor types / Integrated dataset on larotrectinib demonstrated high...

Xarelto, in combination with aspirin, is indicated to reduce the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease / Xarelto, in combination with aspirin, is the only non-vitamin K antag...

The safety and efficacy profile of BAY94-9027 has been demonstrated in more than five years of clinical studies / Prophylaxis with BAY94-9027 enables sustained factor VIII concentrations in the blood over time...

Berlin, September 21, 2018 - Bayer announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Jivi® (BAY94-9027) for the prophylactic treatment of hemophilia A for adults and adolescents 12 years of age or older in J...

Dieter Weinand leaving the company as of November 1, 2018 / Contract extensions for Board of Management members Liam Condon and Dr. Hartmut Klusik

Monsanto business included on prorated basis from June 7 / Group sales advance by 8.5 percent (Fx & portfolio adj.) to 9.481 billion euros / EBITDA before special items increases by 3.9 percent to 2.335 billion euros despite unfavorable currency effe...

Ballerup, Denmark / Leverkusen, Germany, September 4, 2018 - LEO Pharma and Bayer announced today the completion of the relevant closing conditions to allow the transfer of Bayer’s prescription dermatology business to LEO Pharma in the United States....

Monheim/St. Louis, September 3, 2018 - Bayer welcomes the ruling issued today by a Brazilian court that ensures growers in that country will have continued access to glyphosate-based herbicides. "This ruling is very good news for Brazilian growers, ...

Jivi’s extended half-life allows for twice-weekly initial dosing / May be adjusted to every five days and further individually adjusted to less or more frequent dosing

Studies in very sick patient populations reaffirm and further strengthen the safety profile of rivaroxaban / Study results did not show a statistical difference in primary endpoints / COMMANDER HF study evaluated rivaroxaban in patients following an ...

Berlin, August 27, 2018 - Bayer announced today that the marketing authorization application (MAA) for larotrectinib has been submitted to the European Medicines Agency (EMA). Larotrectinib was developed to treat adult and pediatric patients with loc...

Xarelto is the only non-vitamin K antagonist oral anticoagulant (NOAC) indicated in combination with acetylsalicylic acid (ASA) for the prevention of atherothrombotic events in patients with coronary artery disease or symptomatic peripheral artery di...

Leverkusen, August 20, 2018 - Upon application by Bayer, the Hamburg Regional Court on August 20, 2018, prohibited last Thursday’s report by German magazine WirtschaftsWoche claiming that Bayer faces "new trouble" because of further lawsuits against ...

Leverkusen, August 17, 2018 - In reports appearing in its August 17 edition, and in an advance version on August 16, German magazine WirtschaftsWoche states that farmers in Arkansas and South Dakota have filed new class-action lawsuits over Dicamba i...

Legal remedies against jury verdict in California announced

New treatment regimen could offer patients with neovascular age-related macular degeneration (AMD) extended proactive dosing already in the first year, while delivering strong visual gains / Data from ALTAIR study demonstrate sustainability of new ap...

Significant step to bolster LEO Pharma’s role as a leading global dermatology company with its goal of helping 125 million patients by 2025

Positive CHMP opinion based on data from the largest Phase III rivaroxaban study, COMPASS / Once approved, rivaroxaban will be the only non-vitamin K antagonist oral anticoagulant (NOAC) indicated in combination with acetylsalicylic acid (ASA) for th...

Issue of four tranches with maturities of 4 to 11½ years was more than four times oversubscribed

Successful international placement secures long-term financing of the Monsanto acquisition / Issue of eight tranches with maturities of three to 30 years was approximately three times oversubscribed

Leverkusen, June 7, 2018 - Bayer successfully completed the acquisition of Monsanto on Thursday. Shares in the U.S. company will no longer be traded on the New York Stock Exchange, with Bayer now the sole owner of Monsanto Company. Monsanto sharehold...

Largest acquisition in company history to double size of agriculture business / Leading innovation engine in agriculture with pro forma R&D investment of 2.4 billion euros in 2017 / Transaction anticipated to generate significant value / Bayer streng...

Final equity measure associated with the acquisition / Stockholders can acquire 2 new shares for every 23 shares they hold for 81.00 euros per new share